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ABSTRACT
Objective: Some studies have demonstrated that Reaction Time (RT) is longer in patients with 
ADHD which in turn may be associated with educational and occupational impairment and 
increased driving risks. Any alteration on RT which is induced by the treatment in this population 
may have great consequences positively or negatively. This study was designed to examine the 
effects of reboxetine on RT in adults with Attention Deficit-Hyperactivity Disorder (ADHD). 
Methods: A total of 30 adult patients with ADHD who did not suffer from any other major 
psychiatric disorder were eligible to participate in this double blind, placebo controlled study. 
Patients were randomly assigned to receive either reboxetine (4 mg/day for one week, then          
8 mg/day) or placebo for 4 weeks. RT was assessed at baseline and after 4 weeks by validated 
software which collects and analyses the data for auditory and visual stimulants. Numbers of 
correct responses, omission and substitution errors for each stimulus were calculated.
Results: Regarding visual tasks and in comparison with baseline scores, the number of correct 
responses increased significantly and the number of omission errors decreased significantly 
after 4 weeks of treatment (P<0.05) in both groups. However, with regard to auditory tasks 
scores, no significant differences were found at the end of the study compared to the baseline 
in each of the two groups. Additionally, no significant differences were noted between the two 
groups when both visual and auditory tasks were considered. 
Conclusion: Results of this study showed that reboxetine did not affect the RT of the patients 
when both visual and auditory tasks were assessed. Further studies with larger number of patients 
and for a longer period of time are required to confirm the result of this study. 
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INTRODUCTION
Attention Deficit Hyperactivity Disorder (ADHD) is 
a common psychiatric disorder that occurs in 3-7% 
of school aged children (1-4). Many of these children 
do  not  receive  any  treatment  and  ADHD  often 
persists into adulthood (2, 5). The primary symptoms 
of ADHD involve different degrees of inattention, 
hyperactivity, impulsivity and distractibility (2, 5, 
6). Some symptoms of ADHD such as hyperactivity 
usually decrease with increasing age and maturation, 
however  impulsivity  and  inattention  often  remain 
unchanged (5). 
Some studies have shown that children with ADHD 
tend to have longer Stop Signal Reaction Time (SSRT) 
in  comparison  with  the  healthy  population  (6-9). 
Also, results of another study have noted that adults 
with a history of ADHD in childhood have longer 
Reaction Time (RT) (10). Longer RT is associated 
with educational and occupational impairment and 
increases driving risks with fatal consequences (5, 
11). A study which was conducted in the UK with a 
sample size consistsed of 6424 participants and 21 
years follow up, demonstrated that longer reaction 
times and poorer cognitive performance are related 
to an increased risk of mortality (12). Reaction time 
is also important in sport fields (13). 
Pathophysiology  of  ADHD  has  been  related  to 
dysfunction of catecholaminergic neurotransmitters 
system  (1-3).  As  a  result,  stimulants  and           
noradrenaline  reuptake  inhibitors  have  been 
considered as cornerstone of ADHD treatment (1). 
Some  studies  support  using  methylphenidate  (a 
stimulant) as a treatment for ADHD in most adults 
(9,  14).  Due  to  some  side  effects  of  stimulants 
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including changes in appetite and insomnia and due 
to their potential for abuse, the use of non-stimulant 
drugs may be preferred. 
Atomoxetine is a selective inhibitor of noradrenaline 
transporter  that  has  a  minimal  affinity  for  the 
serotonin and dopamine transporters (2, 15, 16). It 
is the first medication approved for the treatment of 
ADHD in adults. It has a safe and efficient profile 
(1) but is rather expensive (17). Reboxetine which 
was first marketed as an antidepressant (18), is a 
selective norepinephrine reuptake inhibitor and has 
a similar transporter/receptor profile as atomoxetine 
(1) and has been recently studied in the treatment of 
ADHD (19-21). 
It  has  been  reported  that  RT  is  longer  in ADHD 
patients (10) and the use of some other drugs including 
CNS-suppressants is also associated with increased 
RT which may lead to unwanted consequences like 
occupational and driving accidents in these patients 
(22, 23). This double blind, randomized, placebo-
controlled trial was designed to examine the effect 
of reboxetine on RT in adults with ADHD. Positive, 
negative or lacks of effect of the drug on RT in the 
study patients were matters of concern in this study.
Patients and methods
Thirty adults 18 years old or older participated in 
this  study.  Since  prevalence  of ADHD  in  parents 
of children with ADHD is relatively high (2), the 
subjects  were  selected  among  parents  of  children 
and adolescents with ADHD who had referred to 
adolescent  psychiatry  clinics  of  Imam  Hossein 
and  Roozbeh  hospitals  affiliated  with  Shaheed 
Beheshti University of Medical Sciences and Tehran 
University  of  Medical  Sciences  respectively.  The 
diagnosis of ADHD was established by psychiatrists 
according to the Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV–TR) criteria (24). The information about 
ADHD history in childhood was confirmed by one of 
the family member of each patient who remembered 
patient’s  manners  and  behaviors  in  childhood.  In 
addition,  each  subject  completed  a  self  reported 
Conner’s  global  index  questionnaire;  those  who 
obtained the minimum score entered the study. 
Demographic information and results of Hamilton 
anxiety and depression questionnaires were collected 
for each person at the beginning of the study. None 
of patients were taking psychotropic medications for 
at least 2 weeks before the initiation of the study. 
Exclusion  criteria  included  presence  of  any  other 
psychiatric disorders such as bipolar mood disorder 
and major depressive disorder, mental retardation, 
major  medical  illness  such  as  hyperthyroidism, 
cardiovascular,  kidney  or  pulmonary  disease, 
pregnancy or lactation, drug or alcohol abuse and 
a  history  of  seizure  disorder.  Patients  who  forgot 
taking at least 4 doses of their medications during 
the whole period of the study or missed at least 3 
sequential doses as well as those with blood pressure 
above 140/90 mmHg were also excluded from the 
study. After verbal explanation of the study, each 
participant signed an informed consent. 
Patients were randomly divided into two groups. One 
group  received  reboxetine  and  the  other  received 
placebo. All subjects received reboxetine or placebo 
for 4 weeks. Reboxetine was started at a dose of 4 
mg once a day in the morning and after one week the 
drug dose was increased to 4 mg twice a day, one in 
the morning and one in the evening. 
All participants were tested using software installed 
on  a  PC  which  was  designed  and  validated  by 
the  authors  under  supervision  of  Islamic  Azad 
University,  Pharmaceutical  Sciences  Branch 
(IAUPS)-information  technology  division.  It 
consisted of two tasks measuring RT to visual and 
auditory stimulants. Test procedures were presented 
either on a computer screen or speakers. Instructions 
were given orally and they were allowed to practice 
each  test  once  to  become  familiar  with  the  task. 
Visual task was included a series of colors (green, 
red,  yellow  and  blue)  presented  in  the  computer 
screen for 1 second. The participants were asked to 
press the right button related to the color as quickly 
as possible after it appeared on the screen. In each 
test,  RT  for  correct  responses,  number  of  correct 
responses,  omission  errors  (lack  of  responses  to 
target stimuli) and/or substitution errors (the number 
of incorrect response instead of the correct one) were 
calculated by the software.
With regard to the auditory task, the participants were 
asked to press the right button related to the played 
sound as quickly as it was heard. RTs for correct 
responses,  number  of  correct  responses,  omission 
errors,  and/or  substitution  errors  were  calculated 
again by the software. 
A total of 30 visual and 30 auditory targets were 
presented. Each participant performed the test at the 
beginning and at the end of the study. The same test 
was performed in both test sections for each patient. 
Statistical  analyses  were  done  by  utilizing  SPSS 
version 13 for windows; an alpha level less than 
of 0.05 was considered as significance of statistical 
association between variables.  Paired sample t test 
was used to evaluate the effect of reboxetine and 
placebo on RT at each group at the beginning and 
end of the study. For comparison between the two 
groups, independent sample t test was used.
RESULTS
Eleven  women  and  7  men  participated  in  the 
reboxetine group, in the control group there were 7 
women and 5 men. 
The  means  age  of  the  patients  in  reboxetine  and 
placebo groups were 31.3 and 32.1 years, respectively 
and the difference was not significant. 
The  number  of  correct  responses,  omission  and 
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stimuli in both groups at the baseline and the end of 
the study are presented in table 1. 
In  visual  tasks  the  number  of  correct  responses 
increased significantly and the number of omission 
errors decreased significantly (P<0.05) at the end of 
the study in comparison with the baseline in both 
groups. In auditory tasks there were no significant 
(NS) differences in both groups; independent sample 
t test showed NS differences between two groups in 
both visual and auditory tasks. However it was noted 
that  there  was  a  trend  toward  more  substitution 
errors in the reboxetine group in comparison with 
the placebo group.(p=0.07)
DISCUSSION
Different  therapeutic  class  of  drugs  such  as 
stimulants, [e.g. methylphenidate (MPH)], Tricycle 
antidepressants  (TCAs)  and  several  non-stimulant 
drugs  such  as  atomoxetine  and  reboxetine  are 
being used to treat ADHD and have been shown to 
be effective in reducing the symptoms of ADHD 
(1,  3,  25-28).  Several  studies  have  shown  that 
methylphenidate  and  other  stimulants  improved 
SSRT in adults and children with ADHD (6, 27-30), 
but they have some adverse effects such as decreased 
appetite, insomnia and potential for abuse (2, 31). 
TCAs  such  as  desipramine,  amitriptyline  and 
imipramine that have been used for the treatment of 
ADHD, may increase RT (22, 23). As a result, these 
drugs  are  associated  with  an  increase  risk  of  car 
accidents with fatal consequences (23). A comparison 
of  the  effect  of  reboxetine  and  amitriptyline  on 
cognitive function and psychomotor performance in 
healthy subjects, showed that reboxetine had little or 
no effect on the performance, however amitriptyline 
increased  RT  (32).  Similarly,  the  driving  risks 
increased  in  subjects  while  taking  TCAs  (23). 
Similar results have been reported in patients with 
major depressive disorder (22). 
Atomoxetine is a selective norepinephrine reuptake 
inhibitor with almost no abuse potential and some 
studies have shown that it can decrease SSRT in 
adults with ADHD (33). 
Theoretically, reboxetine may decrease RT similar to 
atomoxetine. At the end of present study, significant 
differences were observed in the number of correct 
responses and omission errors in comparison with 
the baseline values in both reboxetine and placebo 
groups.  These  findings  were  similar  to  those  in 
previous studies (1, 35). Ferguson et al, compared 
the  effects  of  reboxetine,  paroxetine  and  placebo 
in  depressed  patients  and  found  that  reboxetine 
improved  cognitive  functions  in  comparison  with 
the baseline (36).
Results of present study showed that there were no 
differences in the mean of RT of correct answers 
compared  to  the  baseline  values  in  both  groups. 
Hindmarch examined the effect of reboxetine and 
amitriptyline on psychomotor or cognitive function 
in healthy males. Consistent with the results of this 
study, it was reported that reboxetine had little effect 
on psychomotor or cognitive function. On the other 
hand, amitriptyline, even at low doses, impaired CNS 
function (37). Siepman et al compared the effects of 
                             
Group of the study Reboxetine  (n=18) Placebo (n=12)
Baseline End point Pvalue Baseline End point Pvalue
Visual tasks
 Correct responses   7.5  ±  5.24 12.61± 6.73 <0.001* 11.08±  8.28 16.17 ± 9.57 <0.001*
 Substitution errors   8.72 ± 2.76   9.00± 3.31
0.77
  8.33±  4.14   6.17 ± 4.34
0.126
 Omission errors 13.78 ± 4.85   8.39± 4.02 <0.001* 10.58±  7.14   7.67 ± 6.44 <0.001*
Auditory tasks
Correct responses  4.72  ±  3.48   6.83 ± 3.99 0.052   7.75 ± 4.99   8.08 ± 1.78 0.259
Substitution errors 12.06 ± 4.17 12.11 ± 4.85 0.968 12.5   ± 5.50 13.75 ± 3.17 0.575
Omission errors 13.22 ± 5.14 11.11 ± 5.48 0.172   9.75 ± 6.21   8.17 ± 4.00   0.196
* : Significant differences at the end of the study in comparison with the  baseline in each group (P<0.001)
Table 1. Correct responses, omission and substitution errors at the baseline and at the end of the study.
                         Group of the study Reboxetine (n=18) Placebo (n=12)
Baseline End point P value Baseline End point P value
Visual tasks 0.617 ± 0.159 0.646 ± 0.075 0.426 0.596 ± 0.083 0.632 ± 0.105 0.199
Auditory tasks 0.583 ± 0.201 0.573 ± 0.178 0.827 0.668 ± 0.124 0.610 ± 0.105 0.586
† : The data are in mean ± standard deviation ( in seconds).
Table 2. Mean of reaction time (RT) in the reboxetine and placebo groups at the baseline and at the end of the study†.A comparison of the effects of reboxetine and placebo 234
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